Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03107091 · ClinicalTrials.gov registry record · Phase 2
Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites
A Phase 2 study, sponsored by BioVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03107091 is a Phase 2 study that has completed, run by BioVie. The registered enrollment target is 6 participants.
The verdict
NCT03107091, a Phase 2 study, has completed, sponsored by BioVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Low-dose continuous infusion of terlipressin will be administered to six cirrhotic patients with refractory ascites.
Interventions
- DRUG Terlipressin acetate continuous infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-07-15 |
| Est. Completion | 2019-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03107091
The ClinicalTrials.gov registry entry for NCT03107091 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioVie, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Terlipressin acetate continuous infusion is the first listed.
NCT03107091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03107091 about?
NCT03107091 is a clinical study titled "Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites". Low-dose continuous infusion of terlipressin will be administered to six cirrhotic patients with refractory ascites.
What is the current status of trial NCT03107091?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2017-07-15. Estimated completion is 2019-04-25.
What interventions are being tested in trial NCT03107091?
The interventions under investigation include: Terlipressin acetate continuous infusion (DRUG).
Who is sponsoring clinical trial NCT03107091?
This trial is sponsored by BioVie, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.